Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
NCT ID: NCT03160885
Last Updated: 2025-03-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
794 participants
INTERVENTIONAL
2017-06-12
2019-08-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD).
Secondary objectives:
To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health related quality of life compared with placebo.
Maintenance objective:
To evaluate maintenance of effect with continued tralokinumab dosing up to 52 weeks compared to placebo for subjects achieving clinical response at Week 16.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)
NCT03131648
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3
NCT03363854
Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).
NCT03526861
Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7
NCT03761537
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects achieving a clinical response at Week 16 (defined as IGA of 0 or 1 on a 5-point scale ranging from 0 \[clear\] to 4 \[severe\], or at least 75% reduction in Eczema Area and Severity Index \[EASI\] score from baseline \[EASI75\]) continued into maintenance treatment that continued until Week 52.
Subjects randomized to tralokinumab in the initial treatment period and who achieved a clinical response at Week 16 (defined by IGA 0 or 1, or EASI75) were re-randomized 2:2:1 to one of the following Q2W maintenance regimens stratified by region (Asia, Australia, Europe, and North America) and IGA response at Week 16 (IGA 0/1 or IGA \>1):
* Tralokinumab 300 mg Q2W.
* Tralokinumab 300 mg Q4W (alternating dose administrations tralokinumab 300 mg and placebo).
* Placebo.
Subjects randomized to placebo in the initial treatment period who achieved a clinical response at Week 16 (defined by IGA 0 or 1, or EASI75) continued to receive placebo Q2W in the maintenance treatment period.
Subjects not achieving a clinical response at Week 16 as well as those who met the criteria listed below during maintenance treatment were transferred to open-label tralokinumab 300 mg Q2W treatment with optional use of topical corticosteroid (TCS) up to Week 52.
Transfer to open-label treatment during maintenance:
Subjects with IGA=0 at Week 16: IGA of at least 2 and not achieved EASI75 over at least a 4-week period (i.e. over 3 consecutive visits).
Subjects with IGA=1 at Week 16: IGA of at least 3 and not achieved EASI75 over at least a 4-week period (i.e. over 3 consecutive visits).
Subjects with IGA \>1 at Week 16: not achieved EASI75 over at least a 4-week period (i.e. over 3 consecutive visits).
Subjects transferring to open-label treatment had the option to self-administer tralokinumab in their home after adequate training (at 3 dosing visits in the open-label period after additional consent has been obtained) by site staff at the investigator's discretion.
After completion of the maintenance treatment period (or open-label treatment), all subjects, except for those who entered the open-label long-term extension trial, continued in a 14-week off-treatment follow-up period for the assessment of safety and anti-drug antibody (ADA).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Since tralokinumab and placebo are visually distinct and not matched for viscosity, IMP will be handled and administered by a qualified, unblinded healthcare professional (HCP) at the site who will not be involved in the management of trial subjects and who will not perform any of the assessments.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Initial treatment period - Tralokinumab Q2W
Week 0 to Week 16
Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks
Tralokinumab
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Initial treatment period - Placebo
Week 0 to Week 16 (Initial treatment period):
Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks
Placebo
Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Maintenance treatment period - Tralokinumab Q2W
Week 16 to Week 52
Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks
Tralokinumab
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Maintenance treatment period - Tralokinumab Q4W
Week 16 to Week 52
Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.
Participants in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks
Tralokinumab
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Placebo
Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Maintenance treatment period - Placebo
Week 16 to Week 52
Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks
Placebo
Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Maintenance treatment period - Placebo (tralokinumab naive)
Week 16 to Week 52
Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks
Placebo
Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Open-label treatment - Tralokinumab 300 mg Q2W + optional TCS
Week 16 to Week 52
Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered tralokinumab subcutaneous (SC) injection + optional TCS\* regimen Q2W
OR
Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS regimen Q2W
• TCS = topical corticosteroids
Tralokinumab
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tralokinumab
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
Placebo
Placebo contains the same excipients, in the same concentration only lacking tralokinumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age 18 and above.
3. Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD (33; Appendix 5).
4. Diagnosis of AD for ≥1 year.
5. Subjects who have a recent history (within 1 year before the screening visit) of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable (e.g., due to important side effects or safety risks).
* Inadequate response is defined as failure to achieve and maintain remission or a low disease activity state (comparable to IGA 0=clear to 2=mild) despite treatment with a daily regimen of TCS of medium to higher potency (±TCI as appropriate), applied for at least 28 days or for the maximum duration recommended by the product prescribing information (e.g., 14 days for super potent TCS), whichever is shorter.
* Subjects with documented systemic treatment for AD in the past year are also considered as inadequate responders to topical treatments and are potentially eligible for treatment with tralokinumab after appropriate washout.
* Important side effects or safety risks are those that outweigh the potential treatment benefits and include intolerance to treatment, hypersensitivity reactions, significant skin atrophy, and systemic effects, as assessed by the investigator or by the subject's treating physician.
6. AD involvement of ≥10% body surface area at screening and baseline (visit 3).
7. An EASI score of ≥12 at screening and 16 at baseline.
8. An IGA score of ≥3 at screening and at baseline.
9. A Worst Daily Pruritus numeric rating scale (NRS) average score of ≥4 during the week prior to baseline.
• Worst Daily Pruritus NRS at baseline will be calculated from daily assessments of worst itch severity (Worst Daily Pruritus NRS) during the 7 days immediately preceding randomisation (Day 6 to 0). A minimum of 4 Worst Daily Pruritus NRS scores out of the 7 days is required to calculate the baseline average score. For subjects who do not have at least 4 scores reported during the 7 days immediately preceding the planned randomisation date, randomisation should be postponed until this requirement is met, but without exceeding the 6 weeks maximum duration for screening.
10. Subjects must have applied a stable dose of emollient twice daily (or more, as needed) for at least 14 days before randomisation (refer to exclusion criterion no. 8 for limitations regarding emollients).
11. Women of childbearing potential must use a highly effective\* form of birth control (confirmed by the investigator) throughout the trial and at least for 16 weeks (5 half lives) after last administration of IMP.
* A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year) such as bilateral tubal occlusion, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), sexual abstinence (when this is in line with the preferred and usual life style of the subject), vasectomised partner (given that the subject is monogamous). The subjects must have used the contraceptive method continuously for at least 1 month prior to the pregnancy test at baseline. A female is defined as not being of child-bearing potential if she is postmenopausal (at least 12 months with no menses without an alternative medical cause prior to screening), or surgically sterile (hysterectomy, bilateral salpingectomy or bilateral oophorectomy).
Exclusion Criteria
2. Previous randomisation in tralokinumab trials.
3. Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment, such as scabies, cutaneous lymphoma, or psoriasis.
4. Known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of severity of AD.
5. Use of tanning beds or phototherapy (narrow band ultraviolet B \[NBUVB\], ultraviolet B \[UVB\], ultraviolet A1 \[UVA1\], psoralen + ultraviolet A \[PUVA\]), within 6 weeks prior to randomisation.
6. Treatment with the following medications within 4 weeks prior to randomisation:
* Systemic immunosuppressive/immunomodulating drugs (e.g. methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, Janus kinase inhibitors etc.).
* Systemic corticosteroid use (excludes topical, inhaled, or intranasal delivery).
* Three or more bleach baths during any week within the 4 weeks.
7. Treatment with the following medications within 2 weeks prior to randomisation
* TCS.
* TCI.
* Topical PDE 4 inhibitor.
8. Initiation of treatment of AD with prescription emollients or emollients containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period (subjects may continue using stable doses of such emollients if initiated before the screening visit).
9. Receipt of live attenuated vaccines 30 days prior to the date of randomisation and during the trial including the safety follow-up period.
• Receipt of inactive/killed vaccinations (e.g. inactive influenza) are allowed, provided they are not administered within 5 days before/after any study visit.
10. Receipt of any marketed (i.e. immunoglobulin, anti-IgE) or investigational biologic agent, including dupilumab:
* Any cell-depleting agents including but not limited to rituximab: within 6 months prior to randomisation, or until lymphocyte count returns to normal, whichever is longer.
* Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to randomisation.
11. Receipt of any investigational non-biologic agent within 5 half-lives prior to randomisation.
12. Receipt of blood products within 4 weeks prior to screening.
13. Major surgery within 8 weeks prior to screening, or planned in-patient surgery or hospitalisation during the trial period.
14. Known or suspected allergy or reaction to any component of the IMP formulation.
15. History of any active skin infection within 1 week prior to randomisation.
16. History of a clinically significant infection within 4 weeks prior to randomisation which, in the opinion of the investigator or sponsor's medical expert, may compromise the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the subject's ability to participate in the trial. Clinically significant infections are defined as:
* a systemic infection.
* a serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.
17. A helminth parasitic infection within 6 months prior to the date informed consent is obtained that has not been treated with, or has failed to respond to, standard of care therapy.
18. History of anaphylaxis following any biologic therapy.
19. History of immune complex disease.
20. History of cancer:
* Subjects who have had basal cell carcinoma, localised squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the subject is in remission and curative therapy was completed at least 12 months prior to the date informed consent was obtained.
* Subjects who have had other malignancies are eligible provided that the subject is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained.
21. Tuberculosis requiring treatment within the 12 months prior to screening. Evaluation will be according to local guidelines as per local standard of care.
22. History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral medications as determined by medical history and/or subject's verbal report.
23. History of chronic alcohol or drug abuse within 12 months prior to screening, or any condition associated with poor compliance as judged by the investigator.
24. History of attempted suicide or is at significant risk of suicide (either in the opinion of the investigator or defined as a "yes" to suicidal ideation questions no. 4 or 5 or answering "yes" to suicidal behaviour on the Columbia-Suicide Severity Rating Scale \[C-SSRS\] Screening version).
25. Any disorder, including but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, immunological, psychiatric, or major physical impairment that is not stable, in the opinion of the investigator, and could:
* Affect the safety of the subject throughout the trial.
* Influence the findings of the trial or their interpretations.
* Impede the subject's ability to complete the entire duration of trial.
26. Any clinically significant abnormal findings in physical examination, vital signs, electrocardiogram (ECG), haematology, clinical chemistry, or urinalysis during the screening period, which in the opinion of the investigator, may put the subject at risk because of his/her participation in the trial, or may influence the results of the trial, or the subject's ability to complete entire duration of the trial.
27. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.0 times the ULN (upper limit of normal) at screening.
28. Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb) or hepatitis C virus antibody (anti-HCV) serology at screening. Subjects with positive HBsAb may be randomised provided they are hepatitis B vaccinated and have negative HBsAg and HBcAb.
29. Subjects who are not willing to abstain from donating blood and/or plasma from the time of informed consent and for 16 weeks (5 half-lives) after last dose of IMP.
30. Subjects who are legally institutionalised.
31. Pregnant, breastfeeding, or lactating women.
32. Employees of the trial site or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LEO Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Simpson, MD, MCR
Role: PRINCIPAL_INVESTIGATOR
Department of Dermatology, Oregon Health and Science University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States
California dermatology
Encinitas, California, United States
Advanced SkinCare Surgery & Med Center
Fullerton, California, United States
USC Department of Dermatology
Los Angeles, California, United States
Thiele Dermatology Specialists, Inc
Murrieta, California, United States
Island Dermatology
Newport Beach, California, United States
Therapeutics Clinical Research
San Diego, California, United States
San Luis Dermatology and Laser Clinic
San Luis Obispo, California, United States
Southern California Dermatology, Inc.
Santa Ana, California, United States
Olympian Clinical Research
Clearwater, Florida, United States
Spotlight Research Center, LLC
Miami, Florida, United States
Private Practice - Dr. Tory P. Sullivan
North Miami Beach, Florida, United States
Marietta Dermatology Clinical Research, Inc.
Marietta, Georgia, United States
MedaPhase, Inc.
Newnan, Georgia, United States
Northwestern University
Chicago, Illinois, United States
RUSH University
Chicago, Illinois, United States
Dawes-Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
Kansas City Dermatology, PA
Overland Park, Kansas, United States
Beacon Clinical Research
Quincy, Massachusetts, United States
HFMC New Center One
Detroit, Michigan, United States
The Grekin Skin Institute
Warren, Michigan, United States
Respiratory Medicine Research Institute of Michigan, PLC
Ypsilanti, Michigan, United States
Clinical Studies Group
Henderson, Nevada, United States
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, United States
Corning Center for Clinical Research
Corning, New York, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Sadick Dermatology
New York, New York, United States
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
University of Cincinnati Health Physicians Office
Cincinnati, Ohio, United States
Wright State Physicians
Fairborn, Ohio, United States
Aventiv Research Inc.
Westerville, Ohio, United States
Oregon Dermatology and Research Center
Portland, Oregon, United States
Paddington Testing Company, Inc.
Philadelphia, Pennsylvania, United States
Yardley Dermatology Associates
Yardley, Pennsylvania, United States
Clinical Research Center of the Carolinas
Charleston, South Carolina, United States
Rivergate Dermatology Clinical Research Center
Goodlettsville, Tennessee, United States
Bellaire Dermatology Associates
Bellaire, Texas, United States
Modern Research Associates, PLLC
Dallas, Texas, United States
Austin Institute for Clinical Research, Inc.
Pflugerville, Texas, United States
Progressive Clinical Research
San Antonio, Texas, United States
Woden Dermatology Pty Ltd.
Phillip, Australian Capital Territory, Australia
Skin & Cancer Foundation Australia
Darlinghurst, New South Wales, Australia
St. George Dermatology and Skin Cancer Center
Kogarah, New South Wales, Australia
Veracity Clinical Research
Woolloongabba, Queensland, Australia
Skin & Cancer Foundation Inc.
Carlton, Victoria, Australia
Sinclair Dermatology
East Melbourne, Victoria, Australia
Burswood Dermatology
Victoria Park, Western Australia, Australia
Dr. Chih-ho Hong Medical
Surrey, British Columbia, Canada
Enverus Medical Research
Surrey, British Columbia, Canada
Pacific Derm
Vancouver, British Columbia, Canada
Winnipeg Clinic
Winnipeg, Manitoba, Canada
Wiseman Dermatology Research
Winnipeg, Manitoba, Canada
Brunswick Dermatology Centre
Fredericton, New Brunswick, Canada
Nexus Clinical Research
St. John's, Newfoundland and Labrador, Canada
Eastern Canada Cutaneous Research
Halifax, Nova Scotia, Canada
Kingsway Clinical Research
Etobicoke, Ontario, Canada
Guenther Derm Research Centre
London, Ontario, Canada
Lynderm Research Inc.
Markham, Ontario, Canada
DermEdge Research
Mississauga, Ontario, Canada
Dermatology & Cosmetic Surgery
North Bay, Ontario, Canada
Derm Clinic of Dr. Robern
Ottawa, Ontario, Canada
Skin Centre for Dermatology
Peterborough, Ontario, Canada
Dermatology & Cosmetic Surgery
Richmond Hill, Ontario, Canada
K. Papp
Waterloo, Ontario, Canada
XLR8 Medical Research
Windsor, Ontario, Canada
Dr. David Gratton Dermatologue
Montreal, Quebec, Canada
CRDQ
Québec, Quebec, Canada
Aarhus University Hospital
Aarhus, , Denmark
Bispebjerg Hospital
Hellerup, , Denmark
Gentofte Hospital
Hellerup, , Denmark
Spedali Civili Brescia
Brescia, , Italy
Policlinico-Vittorio Emanuele
Catania, , Italy
Opedale San Salvatore
L’Aquila, , Italy
AOU Pisa
Pisa, , Italy
IRCCS San Gallicano
Rome, , Italy
Policlinico "Agostino Gemelli"
Rome, , Italy
Istituto Clinico Humanitas
Rozzano, , Italy
Centrum Medyczne Gdynia
Gdynia, , Poland
Synexus Polska Gdyni
Gdynia, , Poland
Synexus Polska Katowicach
Katowice, , Poland
Centrum Medyczne PRATIA
Krakow, , Poland
Krakowskie Centrum Medyczne
Krakow, , Poland
"DERMED" Centrum Medyczne Sp.
Lodz, , Poland
Dermoklinika Centrum Medyczne
Lodz, , Poland
Synexus Polska Poznaniu
Poznan, , Poland
Klinika Dermatologii
Rzeszów, , Poland
Chelyabinsk Dermat. Dispensary
Chelyabinsk, , Russia
Federal State Budgetary Institution State Sci. Ctr.
Moscow, , Russia
French clinic of skin diseases
Saint Petersburg, , Russia
Military Medical Academy
Saint Petersburg, , Russia
Pusan National University Hospital
Busan, , South Korea
Chungnam National Univeristy
Daejeon, , South Korea
Chonnam National University Hospital
Gwangju, , South Korea
Soon Chun Hyang University Hospital
Gyeonggi-do, , South Korea
Korea University Ansan Hospital
Gyeonggi-do, , South Korea
St. Mary's Hospital
Incheon, , South Korea
Inha University Hospital
Incheon, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Yonsei University Health Syste
Seoul, , South Korea
Konkuk University Medical Center
Seoul, , South Korea
Chung-Ang University Hospital
Seoul, , South Korea
Hallym University Kangnam Sacr
Seoul, , South Korea
Ninewells Hospital
Dundee, Angus, United Kingdom
Salford Royal Hospital
Salford, Greater Manchester, United Kingdom
Whipps Cross University Hospital
Leytonstone, London, United Kingdom
Harrogate District Hospital
Harrogate, North Yorkshire, United Kingdom
Royal Hallamshire Hospital
Sheffield, South Yorkshire, United Kingdom
East Surrey Hospital
Redhill, Surrey, United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Russells Hall Hospital
Dudley, West Midlands, United Kingdom
Walsall Healthcare NHS Trust
Walsall, West Midlands, United Kingdom
Chapel Allerton Hospital
Leeds, West Yorkshire, United Kingdom
West Suffolk Hospital
Bury St Edmunds, , United Kingdom
The Whittington Hospital NHS
London, , United Kingdom
Guy's Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mayo T, Silverberg JI, Armstrong A, Guttman-Yassky E, Blauvelt A, Esdaile B, Kabashima K, Gooderham M, Kircik L, Schneider S, Bennike N, von Eyben R, Martel BC, Ropke MA, Katoh N, Alexis AF. Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials. Am J Clin Dermatol. 2025 Oct 21. doi: 10.1007/s40257-025-00985-1. Online ahead of print.
Reich K, Langley RG, Salvador JFS, Staumont-Salle D, Costanzo A, Pink AE, Paller AS, Katoh N, Wollenberg A, Warren RB, Blauvelt A, Oland CB, Tindberg AM, Gjerum L, Simpson EL. Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trials. Br J Dermatol. 2025 Aug 29:ljaf309. doi: 10.1093/bjd/ljaf309. Online ahead of print.
Paller AS, Soong W, Boguniewicz M, Geng B, Thyssen JP, Bennike N, Schneider S, Wollenberg A. Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities. Ann Allergy Asthma Immunol. 2025 Oct;135(4):425-433.e4. doi: 10.1016/j.anai.2025.06.022. Epub 2025 Jun 22.
Chovatiya R, Ribero S, Wollenberg A, Park CO, Silvestre JF, Hong HC, Seneschal J, Saeki H, Thyssen JP, Oland CB, Gjerum L, Maslin D, Blauvelt A. Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years. Am J Clin Dermatol. 2025 Jul;26(4):587-601. doi: 10.1007/s40257-025-00931-1. Epub 2025 Mar 14.
Simpson EL, Blauvelt A, Silverberg JI, Cork MJ, Katoh N, Mark T, Schneider SKR, Wollenberg A. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1. Am J Clin Dermatol. 2024 Jan;25(1):139-148. doi: 10.1007/s40257-023-00817-0. Epub 2023 Oct 7.
Simpson EL, Pink AE, Blauvelt A, Gooderham M, Armstrong AW, Worm M, Katoh N, Peris K, Puig L, Barbarot S, Mark T, Steffensen LA, Tindberg AM, Wollenberg A. Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials. Am J Clin Dermatol. 2023 Nov;24(6):939-952. doi: 10.1007/s40257-023-00806-3. Epub 2023 Sep 8.
Blauvelt A, Gooderham M, Bhatia N, Langley RG, Schneider S, Zoidis J, Kurbasic A, Armstrong A, Silverberg JI. Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3. Dermatol Ther (Heidelb). 2022 Nov;12(11):2499-2516. doi: 10.1007/s13555-022-00805-y. Epub 2022 Sep 24.
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, Osterdal ML, Simpson EL; ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-004201-13
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
LP0162-1326
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.